Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Using Experimental Models, Researchers Hope to Target Down Syndrome Gene

By Kenny Walter | June 11, 2019

A team of researchers from Rutgers University has made progress toward better understanding—and potentially someday targeting—human chromosome 21 gene OLIG2, a gene that impairs cognitive function in those with Down Syndrome. 

Typical  babies are born with a pair of 23 chromosomes, while babies with Down Syndrome have an extra copy of chromosome 21. This results in changes in how the body and brain develop, leading to both mental and physical problems. By focusing on chromosome 21 gene OLIG2 as a potential target for prenatal therapy, researchers are hoping to reverse abnormal embryonic brain development, rebalancing the two types of neurons in the brain—excitatory and inhibitory—and potentially improving cognitive function after birth

The team collected skin cells from Down Syndrome patients that were genetically reprogrammed to human-induced pluripotent stem cells (hiPSCs). hiPSCs resemble embryonic stem cells, the special cells that can develop into many different types of cells, including brain cells, during early life and growth and are useful tools for drug development and disease modeling. 

The researchers then used a pair of experimental models—a living 3D organoid model of an early developing brain and a mouse brain model that was implanted with the human cells within a day of the mouse’s birth.

The researchers found that the inhibitory neurons were overproduced in both the 3D model and the mouse brain, while the adult mice used in the study developed impaired memory, and that the OLIG2 gene plays a crucial role causing these effects. The researchers were able to inhibit the gene, which led to improvements in the mice subjects.

Peng Jiang, assistant professor in the Department of Cell Biology and Neuroscience at Rutgers University–New Brunswick, explained in an exclusive interview with R&D Magazine that these cells could lead to research breakthroughs.

“We culture those brain cells in three-dimensional conditions and those brain cells can actually form clusters, where inside the cluster they form certain structures that mimic the early human fetal brain or embryonic brain development,” Jiang said. “Those stem cells provide a powerful tool for us to better understand disease mechanisms and provide a platform for future drug screening.

Using animal models to study Down syndrome is very challenging because the mice don’t have chromosome 21, so the genes are distributed to different amounts of chromosomes and because of that most of the mouse models only have distribution of part of the human 21 genes, leading to discrepancies. The organoid model gives us a new opportunity to look at the brain development in the early fetal stages. This way we actually have a mouse model that contains a large number of human cells to allow us to further examine the properties of the diseased human neurons,” he added.

According to Jiang, the study could spark future research for neurodevelopmental disorders such as autism spectrum disorder. He also said the duel model approach could provide scientists with a better understanding of Alzheimer’s disease, which Down syndrome patients commonly develop.

“In a later stage of the Down syndrome patient’s life they tend to develop Alzheimer’s disease, around their 60’s,” Jiang said. “This gives us a good opportunity to understand how an abnormal expression of those genes cause an abnormal brain development and also lead to an early onset of neurodegeneration Alzheimer’s disease in those patients. 

Jiang explained what the next step for the researchers would be.

“As a next step we really want to see if we can use small molecule drugs that can target that gene and see if these drugs can help suppress the gene and improve the behavior performance of animals,” he said.   

According to the U.S. Centers for Disease Control and Prevention, about 6,000 babies are born each year in the U.S. with Down syndrome.

The study was published in Cell Stem Cell. 


Filed Under: Neurological Disease

 

Related Articles Read More >

FDA expands Vizamyl label to include quantification and therapy monitoring, creating new competitive edge
AbbVie announces head-to-head results challenging migraine treatment status quo
Human study tracks brain’s glymphatic flow in real time, opening Alzheimer’s drug avenues
An 8-year-old patient with gangliosidosis demonstrates improved mobility, walking unassisted on a soccer field after treatment with N-acetyl-L-leucine. (Still from video footage; parental consent obtained for use).
Modified amino acid approved for Niemann–Pick shows promise in early Parkinson’s research
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE